Effects of vaginal lactobacilli in Chlamydia trachomatis infection

International Journal of Medical Microbiology

Volumn 304, Issue 5-6, 2014, Pages 654-661

  Mastromarino, Paola ^a   Di Pietro, Marisa ^a   Schiavoni, Giovanna ^a   Nardis, Chiara ^a   Gentile, Massimo ^a   Sessa, Rosa ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

C. trachomatis; Genital infections; Herpes simplex type 2 virus; Persistent chlamydial forms; Vaginal lactobacilli

Indexed keywords

CELL SURFACE RECEPTOR;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CELL ADHESION; CELL GROWTH; CELL INTERACTION; CELL PROLIFERATION; CELL STRUCTURE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; EPITHELIUM CELL; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; INFECTION RISK; LACTOBACILLUS BREVIS; LACTOBACILLUS SALIVARIUS; MIXED INFECTION; VAGINA FLORA; ANIMAL; BACTERIUM ADHERENCE; CHLAMYDIA INFECTIONS; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; MICROBIOLOGY; ORGANISMAL INTERACTION; PATHOLOGY; PHYSIOLOGY; VAGINA;

ANIMALS; BACTERIAL ADHESION; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FEMALE; HUMANS; LACTOBACILLUS BREVIS; MICROBIAL INTERACTIONS; VAGINA;

EID: 84903817647     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2014.04.006     Document Type: Article

References (38)

1. Allsworth J.E., Peipert J.F. Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Obstet. Gynecol. 2007, 109:114-120.
2. Amaretti A.L., di Nunzio M., Pompei A., Raimondi S., Rossi M., Bordoni A. Antioxidant properties of potentially probiotic bacteria: in vitro and in vivo activities. Appl. Microbiol. Biotechnol. 2013, 97:809-817.
3. Batteiger B.E., Tu W., Ofner S., Van Der Pol B., Stothard D.R., Orr D.P., Katz B.P., Fortenberry J.D. Repeated Chlamydia trachomatis genital infections in adolescent women. J. Infect. Dis. 2010, 201:42-51.
4. Beatty W.L., Byrne G.I., Morrison R.P. Repeated and persistent infection with Chlamydia and the development of chronic inflammation and disease. Trends Microbiol. 1994, 2:94-98.
5. Benedetti J.K., Zeh J., Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann. Intern. Med. 1999, 131:14-20.
6. Bragina E.Y., Gomberg M.A., Dmitriev G.A. Electron microscopic evidence of persistent chlamydial infection following treatment. J. Eur. Acad. Dermatol. Venereol. 2001, 15:405-409.
7. Brotman R.M., Klebanoff M.A., Nansel T.R., Yu K.F., Andrews W.W., Zhang J., Schwebke J.R. Bacterial vaginosis assessed by gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection. J. Infect. Dis. 2010, 202:1907-1915.
8. Cherpes T.L., Meyn L.A., Krohn M.A., Lurie J.G., Hillier S.L. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin. Infect. Dis. 2003, 37:319-325.
9. Conti C., Malacrino C., Mastromarino P. Inhibition of herpes simplex virus type 2 by vaginal lactobacilli. J. Physiol. Pharmacol. 2009, 6:19-26.
10. Dean D., Suchland R.J., Stamm W.E. Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping. J. Infect. Dis. 2000, 182:909-916.
11. Deka S., Vanover J., Dessus-Babus S., Whittimore J., Howett M.K., Wyrick P.B., Schoborg R.V. Chlamydia trachomatis enters a viable but non-cultivable (persistent) state within herpes simplex virus type 2 (HSV-2) co-infected host cells. Cell. Microbiol. 2006, 8:149-162.
12. Deka S., Vanover J., Sun J., Kintner J., Whittimore J., Schoborg R.V. An early event in the herpes simplex virus type-2 replication cycle is sufficient to induce Chlamydia trachomatis persistence. Cell. Microbiol. 2007, 9:725-737.
13. Di Pietro M., Tramonti A., De Santis F., De Biase D., Schiavoni G., Filardo S., Zagaglia C., Sessa R. Analysis of gene expression in penicillin G induced persistence of Chlamydia pneumoniae. J. Biol. Regul. Homeost. Agents 2012, 26:277-284.
14. Finan R.R., Musharrafieh U., Almawi W.Y. Detection of Chlamydia trachomatis and herpes simplex virus type 1 or 2 in cervical samples in human papilloma virus (HPV)-positive and HPV-negative women. Clin. Microbiol. Infect. 2006, 12:927-930.
15. Fleming D.T., McQuillan G.M., Johnson R.E., Nahmias A.J., Aral S.O., Lee F.K., Louis E.S. Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 1997, 337:1105-1111.
16. Geisler W.M., Lensing S.Y., Press C.G., Hook E.W. Spontaneous resolution of genital Chlamydia trachomatis infection in women and protection from reinfection. J. Infect. Dis. 2013, 207:1850-1856.
17. Hillier S.L., Krohn M.A., Klebanoff S.J., Eschenbach D.A. The relationship of hydrogen peroxide-producing lactobacilli to bacterial vaginosis and genital microflora in pregnant women. Obstet. Gynecol. 1992, 79:369-373.
18. Hogan R.J., Mathews S.A., Mukhopadhyay S., Summersgill J.T., Timms P. Chlamydial persistence: beyond the biphasic paradigm. Infect. Immun. 2004, 72:1843-1855.
19. Kaushik J.K., Kumar A., Duary R.K., Mohanty A.K., Grover S., Batish V.K. Functional and probiotic attributes of an indigenous isolate of Lactobacillus plantarum. PLoS ONE 2009, 4:e8099.
20. Kwaśniewska A., Korobowicz E., Zdunek M., Skoczyński M., Kwaśniewski W., Daniłoś J., Goździcka-Józefiak A. Prevalence of Chlamydia trachomatis and herpes simplex virus 2 in cervical carcinoma associated with human papillomavirus detected in paraffin-sectioned samples. Eur. J. Gynaecol. Oncol. 2009, 30:65-70.
21. Looker K.J., Garnett G.P., Schmid G.P. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull. World Health Organ. 2008, 86:805-812. A.
22. Maggi L., Mastromarino P., Macchia S., Brigidi P., Pirovano F., Matteuzzi D., Conte U. Technological and biological evaluation of tablets containing different strains of lactobacilli for vaginal administration. Eur. J. Pharm. Biopharm. 2000, 50:389-395.
23. Mastromarino P., Brigidi P., Macchia S., Maggi L., Pirovano F., Trinchieri V., Conte U., Matteuzzi D. Characterization and selection of vaginal Lactobacillus strains for the preparation of vaginal tablets. J. Appl. Microbiol. 2002, 93:884-893.
24. Mastromarino P., Cacciotti F., Masci A., Mosca L. Antiviral activity of Lactobacillus brevis towards herpes simplex virus type 2: role of cell wall associated components. Anaerobe 2011, 17:334-336.
25. Mylonas I. Female genital Chlamydia trachomatis infection: where are we heading?. Arch. Gynecol. Obstet. 2012, 285:1271-1285.
26. Ness R.B., Soper D.E., Richter H.E., Randall H., Peipert J.F., Nelson D.B., Schubeck D., McNeeley S.G., Trout W., Bass D.C., Hutchison K., Kip K., Brunham R.C. Chlamydia antibodies, chlamydia heat shock protein and adverse sequelae after pelvic inflammatory disease: the PID Evaluation and Clinical Health (PEACH) Study. Sex. Transm. Dis. 2008, 35:129-135.
27. Paavonen J., Teisala K., Heinonen P.K., Aine R., Miettinen A., Lehtinen M., Grönroos P. Endometritis and acute salpingitis associated with Chlamydia trachomatis and herpes simplex virus type two. Obstet. Gynecol. 1985, 65:288-291.
28. Patton D.L., Askienazy-Elbhar M., Henry-Suchet J., Campbell L.A., Cappuccio A., Tannous W., Wang S.P., Kuo C.C. Detection of Chlamydia trachomatis in fallopian tube tissue in women with postinfectious tubal infertility. Am. J. Obstet. Gynecol. 1994, 171:95-101.
29. Prusty B.K., Bohme L., Bergmann B., Siegl C., Krause E., Mehlitz A., Rudel T. Imbalanced oxidative stress causes chlamydial persistence during non-productive human Herpes Virus co-infection. PLoS ONE 2012, 7:e47427.
30. Redondo-Lopez V., Cook R.L., Sobel J.D. Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev. Infect. Dis. 1990, 12:856-872.
31. Schwebke J.R., Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am. J. Obstet. Gynecol. 2007, 196:517e1-517e6.
32. Shaw K., Coleman D., O'Sullivan M., Stephens N. Public health policies and management strategies for genital Chlamydia trachomatis infection. Risk Manage. Healthcare Policy 2011, 4:57-65.
33. Vanover J., Sun J., Deka S., Kintner J., Duffourc M.M., Schoborg R.V. Herpes simplex virus co-infection-induced Chlamydia trachomatis persistence is not mediated by any known persistence inducer or anti-chlamydial pathway. Microbiology 2008, 154:971-978.
34. Vanover J., Kintner J., Whittimore J., Schoborg R.V. Interaction of herpes simplex virus type 2 (HSV-2) glycoprotein D with the host cell surface is sufficient to induce Chlamydia trachomatis persistence. Microbiology 2010, 156:1294-1302.
35. Wald A., Zeh J., Selke S., Warren T., Ryncarz A.J., Ashley R., Krieger J.N., Corey L. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N. Engl. J. Med. 2000, 342:844-850.
36. Wiesenfeld H.C., Hillier S.L., Krohn M.A., Landers D.V., Sweet R.L. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin. Infect. Dis. 2003, 36:663-668.
37. World Health Organization Sexually Transmitted Bacterial Infections. (accessed 25.06.13). http://www.who.int/vaccine_research/documents/Chapter6_STI_New.pdf.
38. Wyrick P.B. Chlamydia trachomatis persistence in vitro: an overview. J. Infect. Dis. 2010, 201:S88-S95.